Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
| العنوان: | Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) |
|---|---|
| المؤلفون: | Solis-Hernandez, Mª Pilar, Fernandez del Valle, Ana, Carmona-Bayonas, Alberto, García-Carbonero, Rocío, Custodio, Ana, Benavent, Marta, Alonso-Gordoa, Teresa, Nuñez-Valdovino, Bárbara, Sanchez Canovas, Manuel, Matos, Ignacio, Alonso, Vicente, Lopez, Carlos, Viudez, Antonio, Izquierdo, Marta, Calvo-Temprano, David, Grande, Enrique, Capdevila Castillón, Jaume, Jimenez-Fonseca, Paula, Universitat Autònoma de Barcelona, Vall d'Hebron Institut d'Oncologia |
| المصدر: | British Journal of Cancer Digital.CSIC. Repositorio Institucional del CSIC instname Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona |
| بيانات النشر: | Springer Nature, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, medicine, Confidence Intervals, Sunitinib, Humans, Progression-free survival, Prospective Studies, Prospective cohort study, Response Evaluation Criteria in Solid Tumors, Aged, Proportional Hazards Models, Aged, 80 and over, Proportional hazards model, business.industry, Middle Aged, medicine.disease, Confidence interval, Progression-Free Survival, Tumor Burden, Pancreatic Neoplasms, Neuroendocrine Tumors, Neuroendocrine cancer, 030220 oncology & carcinogenesis, Radiological weapon, Female, Cancer imaging, business, Tomography, X-Ray Computed, Progressive disease, medicine.drug |
| الوصف: | [Background] The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. [Method] A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. [Results] One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7–15.9) and 15.8 months (95% CI, 13.9–25.7). PFS by Choi (Kendall’s τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall’s τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. [Conclusion] Choi criteria were able to capture sunitinib’s activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug. |
| وصف الملف: | application/pdf |
| تدمد: | 1532-1827 0007-0920 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f812b5d9de10862388b7d74522b1e02Test http://hdl.handle.net/10261/212589Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1f812b5d9de10862388b7d74522b1e02 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|